101
|
Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, Decroos A, Gorvel L, Goubard A, Bouabdallah R, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D. Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e20040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20040 Background: Advanced stage cutaneous T-cell lymphomas (CTCLs) remain an unmet medical need. Immunomodulatory agents such as mogamulizumab, anti-KIR3DL2 and brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate (ADC) coupled to monomethyl-auristatin-E (MMAE), provided encouraging results but new targeted therapies are needed. Inducible Co-Stimulator (ICOS), a T-cell costimulatory receptor involved in the development of CTCLs, arouses interest. Methods: We used immunohistochemistry to study ICOS expression in skin biopsies of 23 patients with early-stage mycosis fungoides (MF), 12 with transformed MF (TMF) and 17 with Sézary Syndrome (SS), at diagnosis or in relapse. ICOS expression by circulating Sézary cells and regulatory T cells (Tregs) in patients with SS was evaluated using flow cytometry, and compared to healthy donors (HD) lymphocytes. In 5 patients with SS, we also analyzed concomitant biopsies from involved nodes. Then, we investigated the efficacy of anti-ICOS ADCs generated by coupling murine anti-ICOS monoclonal antibodies with MMAE, in comparison to BV. We used ICOS+ CTCL cell lines (MyLa and MJ), murine xenograft models with MyLa and ICOS+ Patient Derived Xenografts (PDXs) from patients with SS and angioimmunoblastic T-cell lymphoma (AITL). Results: ICOS was highly expressed by the cutaneous atypical lymphocytic infiltrates in respectively 61%, 75% and 88% of patients with early-stage MF, TMF and SS, such as in the 5 patients with node involvement. ICOS expression by circulating Sézary cells was strong: 69±7.3% versus 38.8±7.1% of non-tumoral CD4+ cells ( p< 0.009; CI95%: 8.7-51.6); and 31±3.2% of CD4+ cells in HD ( p< 0.0001; CI95%:20.3-46.3). Percentages of ICOS+ Tregs were significantly higher in patients with SS than in HD. In CTCL cell lines, we observed a significant dose-dependent decrease in cell viability in the presence of anti-ICOS ADCs. In a mouse xenograft model (MyLa), anti-ICOS ADCs provided a longer overall survival (OS) than BV (HR = 15.2;CI95%:3.2-71.1; p< 0.0006). Finally, in ICOS+ PDXs anti-ICOS ADCs significantly improved OS, and reduced the number of tumor cells in the blood, bone marrow and spleen. No evidence of ADC toxicity was observed in treated mice. Conclusions: All together our results show that ICOS is a therapeutic target of interest in CTCLs and provide the preliminary basis for a therapeutic trial
Collapse
Affiliation(s)
- Florent Amatore
- Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France, Marseille, France
| | - Nicolas Ortonne
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, 94220 Créteil, France, Créteil, France
| | - Marc Lopez
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Florence Orlanducci
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Rémy Castellano
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Hôpital Henri-Mondor, 94220 Créteil, France, Créteil, France
| | - Amandine Decroos
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, 94220 Créteil, France, Créteil, France
| | - Laurent Gorvel
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Armelle Goubard
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | | | - Nathalie Bonnet
- Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France, Marseille, France
| | - Jean-Jacques Grob
- Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix-Marseille Université, Marseille, France, Marseille, France
| | - Philippe Gaulard
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Martine Bagot
- AP-HP, Hôpital Saint-Louis, Unité d’Oncodermatologie, Département de Dermatologie, Paris, France
| | | | - Philippe Berbis
- Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France, Marseille, France
| | - Daniel Olive
- Centre De Recherche En Cancérologie De Marseille, Inserm U1068, Cnrs U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
102
|
Assier H, Ingen-Housz-Oro S, Zehou O, Hirsch G, Chosidow O, Wolkenstein P. Strong reactions to diltiazem patch tests: Plea for a low concentration. Contact Dermatitis 2020; 83:224-225. [PMID: 32281655 DOI: 10.1111/cod.13554] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Revised: 04/02/2020] [Accepted: 04/09/2020] [Indexed: 01/15/2023]
Affiliation(s)
- Haudrey Assier
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Ouidad Zehou
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Gaelle Hirsch
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Pierre Wolkenstein
- Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| |
Collapse
|
103
|
Bourgeois A, Colin A, Redlich J, de Prost N, Ingen-Housz-Oro S. Maladies rares en dermatologie : rôle du service social pour les patients adultes. Exemple de la nécrolyse épidermique. Ann Dermatol Venereol 2020; 147:318-321. [DOI: 10.1016/j.annder.2020.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Revised: 11/24/2019] [Accepted: 01/10/2020] [Indexed: 10/25/2022]
|
104
|
Lalevée S, Catano J, Ingen-Housz-Oro S, Surenaud M, Tran Van Nhieu J, Schlemmer F, Bendib I, Mekontso-Dessap A, Hue S, de Prost N. Acute lung injury in mechanically ventilated patients with epidermal necrolysis: an exposed-unexposed retrospective cohort study. Burns & Trauma 2020; 8:tkaa041. [PMID: 33324706 PMCID: PMC7723417 DOI: 10.1093/burnst/tkaa041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 10/13/2020] [Accepted: 10/22/2020] [Indexed: 11/13/2022]
Affiliation(s)
- S Lalevée
- Service de dermatologie, AP-HP, hôpital Henri Mondor, Créteil, France
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
| | - J Catano
- Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil Cedex 94010, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, AP-HP, hôpital Henri Mondor, Créteil, France
- EA7379 EpidermE, UPEC, Créteil, France
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - M Surenaud
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
| | - J Tran Van Nhieu
- Service d’Anatomopathologie, AP-HP, hôpital Henri Mondor, Créteil, France
| | - F Schlemmer
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
- Unité de Pneumologie, Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil Cedex 94010, France
| | - I Bendib
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
- Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil Cedex 94010, France
- Groupe de Recherche Clinique CARMAS, Faculté de Santé de Créteil, Université Paris Est Créteil, Créteil Cedex 94010, France
| | - A Mekontso-Dessap
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
- Groupe de Recherche Clinique CARMAS, Faculté de Santé de Créteil, Université Paris Est Créteil, Créteil Cedex 94010, France
| | - S Hue
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
- AP-HP, Département d'Hématologie et d'Immunologie biologiques, Groupe hospitalo-universitaire Chenevier Mondor, Assistance Publique-Hôpitaux de Paris F-94010 Créteil, France
| | - N de Prost
- Université Paris Est Créteil, INSERM U955, IMRB, F-94010 Créteil, France
- Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil Cedex 94010, France
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
- Groupe de Recherche Clinique CARMAS, Faculté de Santé de Créteil, Université Paris Est Créteil, Créteil Cedex 94010, France
| |
Collapse
|
105
|
Gaudin O, Deschamps O, Duong TA, Gener G, Paul M, Luciani A, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S, Assier H. Cutaneous tests and interest of iobitridol in non-immediate hypersensitivity to contrast media: a case series of 43 patients. J Eur Acad Dermatol Venereol 2019; 34:e178-e180. [PMID: 31814161 DOI: 10.1111/jdv.16139] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- O Gaudin
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - O Deschamps
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - T A Duong
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - G Gener
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - M Paul
- Pharmacology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,EpidermE, Univ Paris Est Creteil, Créteil, France
| | - A Luciani
- Radiology Department, AP-HP, Henri Mondor hospital, Créteil, France
| | - O Chosidow
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - P Wolkenstein
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - S Ingen-Housz-Oro
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France.,EpidermE, Univ Paris Est Creteil, Créteil, France
| | - H Assier
- Dermatology department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| |
Collapse
|
106
|
Ingen-Housz-Oro S. Quoi de neuf en dermatologie clinique? Ann Dermatol Venereol 2019; 146:12S1-12S10. [DOI: 10.1016/s0151-9638(20)30100-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
107
|
Hotz C, Sbidian E, Ingen-Housz-Oro S, Chosidow O, Wolkenstein P. Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option. Acta Derm Venereol 2019; 99:1170-1171. [PMID: 31314122 DOI: 10.2340/00015555-3268] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Claire Hotz
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.
| | | | | | | | | |
Collapse
|
108
|
Bérot V, Gener G, Ingen-Housz-Oro S, Gaudin O, Paul M, Chosidow O, Wolkenstein P, Assier H. Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol 2019; 34:787-794. [PMID: 31571276 DOI: 10.1111/jdv.15986] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 09/11/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Cross-reactivity among beta-lactam antibiotics (BL) is essentially reported in immediate hypersensitivity. OBJECTIVES To evaluate cross-reactivity beyond BLs in patients with non-immediate cutaneous adverse drug reaction (non-immediate CADR) managed in a dermatology reference centre of toxic bullous and severe CADRs. PATIENTS/MATERIALS/METHODS We conducted a retrospective single-centre study in consecutive patients consulting between 2010 and 2018 with an active BL-suspected non-immediate CADR and explored by cutaneous tests [patch tests (PT) and intradermal tests (P-IDR)] for at least three penicillin's subclasses and amino- and non-amino-cephalosporins (at least one aminocephalosporin). Cross-reactivity among subclasses was investigated for patients with positive tests. RESULTS We included 56 patients, among whom 46 amoxicillin-suspected were and seven cephalosporin-suspected. Twenty-nine had severe CADR, and 27 had non-immediate maculopapular exanthema (MPE). Twenty-two had positive tests (18 for AS and four for CS). Among the 18 positive amoxicillin-suspected, 10 (55.6%) showed cross-reactivity with one or more other BL: 9 (50%) with another penicillin and 3 (16.5%) with a non-aminocephalosporin. No amoxicillin- or cephalosporin-suspected patient showed cross-reactivity with aztreonam or carbapenems. P-IDR showed cross-reactivity only once. CONCLUSION After a suspected BL-induced non-immediate CADR, a large allergologic exploration is needed to confirm the diagnosis and evaluate cross-reactivity. In our population including cases of severe CADRs and MPE with late delay of onset, cross-reactivity was frequent and PT was sufficient to this purpose. The frequent cross-reactivity among penicillins encourages stopping this whole family and to test cephalosporins, aztreonam and carbapenems for which cross-allergies are rarer.
Collapse
Affiliation(s)
- V Bérot
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France
| | - G Gener
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France
| | - S Ingen-Housz-Oro
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France.,EA7379 EpidermE, UPEC, Créteil, France
| | - O Gaudin
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France
| | - M Paul
- EA7379 EpidermE, UPEC, Créteil, France.,Department of Pharmacy, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - O Chosidow
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France.,Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - P Wolkenstein
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France.,Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - H Assier
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, Créteil, France
| |
Collapse
|
109
|
Ingen-Housz-Oro S, Alves A, Colin A, Ouedraogo R, Layese R, Canoui-Poitrine F, Chosidow O, Mekontso-Dessap A, Wolkenstein P, de Prost N. Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. Br J Dermatol 2019; 182:916-926. [PMID: 31385287 DOI: 10.1111/bjd.18387] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/31/2019] [Indexed: 12/18/2022]
Abstract
BACKGROUND Few studies have investigated the global burden of sequelae and health-related quality of life (HRQoL) for survivors of epidermal necrolysis (EN). OBJECTIVES To investigate the long-term HRQoL for survivors of EN using validated instruments. METHODS We conducted a single-centre study that enrolled patients who were admitted for EN between 2010 and 2017. HRQoL was assessed via phone interview using the Short Form (SF)-36 questionnaire, Hospital Anxiety and Depression (HAD) scale, Impact of Event Scale-Revised, and general quality-of-life outcomes, including EN-specific sequelae. The primary outcome measure was the physical component summary (PCS) score of the SF-36. RESULTS In total, 57 survivors of EN [19 (33%) with intensive care unit (ICU) admission] were interviewed via telephone at a median of 3·6 years (1·9-6·1) after hospital discharge. The median PCS score was 0·44 SDs below that of the age- and sex-matched reference population and was significantly lower for survivors of EN who were admitted to the ICU vs. those who were not [43·7 (28·7-49·3) vs. 51·2 (39·4-56·5), P = 0·042]. The proportion of patients with EN who had HAD-anxiety score ≥ 8 or HAD-depression score ≥ 5 was 54% and 21%, respectively. Physical and mental outcomes did not differ between patients with EN who were admitted to the ICU and survivors of septic shock. Reported EN-specific sequelae were cutaneous (77%), ocular (70%), psychological (60%), dental/oral (49%), genital (30%) and respiratory (18%), with median intensity on a visual analogue scale. CONCLUSIONS Our study confirms the major burden and long-term impact of EN on quality of life for survivors and emphasizes the need for prolonged close follow-up after the acute phase. What's already known about this topic? Long-term sequelae have been reported in 90% of survivors of epidermal necrolysis (EN). Few studies have investigated the global burden of sequelae and health-related quality of life (HRQoL) in survivors of EN. What does this study add? Survivors of EN, particularly those admitted to the intensive care unit, had poorer physical HRQoL than the French reference population but had comparable HRQoL to survivors of septic shock. Survivors of EN exhibited symptoms of anxiety, depression and post-traumatic stress syndrome. The most frequent sequelae were cutaneous, ocular and psychological, with visual analogue scale scores of 5/10 and 6/10. These results confirm the burden of EN on quality of life.
Collapse
Affiliation(s)
- S Ingen-Housz-Oro
- Service de Dermatologie, Créteil, France.,Centre National de Référence des Dermatoses Bulleuses Toxiques, Créteil, France.,EA7379 EpidermE, UPEC, Créteil, France
| | - A Alves
- Service de Réanimation Médicale, Créteil, France
| | - A Colin
- Service de Dermatologie, Créteil, France.,Centre National de Référence des Dermatoses Bulleuses Toxiques, Créteil, France
| | - R Ouedraogo
- Service de Réanimation Médicale, Créteil, France
| | - R Layese
- Service de Santé Publique, Hôpital Henri Mondor, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France.,Clinical Epidemiology And Ageing Unit, DHU A-TVB, IMRB-EA 7376 CEpiA, Université Paris-Est UPEC, Créteil, France
| | - F Canoui-Poitrine
- Service de Santé Publique, Hôpital Henri Mondor, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France.,Clinical Epidemiology And Ageing Unit, DHU A-TVB, IMRB-EA 7376 CEpiA, Université Paris-Est UPEC, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Créteil, France.,Centre National de Référence des Dermatoses Bulleuses Toxiques, Créteil, France
| | - A Mekontso-Dessap
- Service de Réanimation Médicale, Créteil, France.,Groupe de Recherche Clinique CARMAS, Université Paris-Est Créteil, IMRB, Créteil, France
| | - P Wolkenstein
- Service de Dermatologie, Créteil, France.,Centre National de Référence des Dermatoses Bulleuses Toxiques, Créteil, France
| | - N de Prost
- Centre National de Référence des Dermatoses Bulleuses Toxiques, Créteil, France.,Service de Réanimation Médicale, Créteil, France.,Groupe de Recherche Clinique CARMAS, Université Paris-Est Créteil, IMRB, Créteil, France
| |
Collapse
|
110
|
Gaudin O, Toukal F, Hua C, Ortonne N, Assier H, Jannic A, Giménez-Arnau E, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S. Association Between Severe Acute Contact Dermatitis Due to Nigella sativa Oil and Epidermal Apoptosis. JAMA Dermatol 2019; 154:1062-1065. [PMID: 30073256 DOI: 10.1001/jamadermatol.2018.2120] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Importance Nigella sativa oil (NSO) is widely used for cosmetic and culinary purposes. Cases of severe acute contact dermatitis due to NSO are poorly described, with no histologic description. Objectives To describe the clinical and histologic features of severe acute contact dermatitis due to NSO and investigate the components responsible for such eruptions. Design, Setting, and Participants A case series study of 3 patients with contact dermatitis admitted to the dermatology department between August 21, 2009, and February 19, 2017, was conducted. All patients had been referred to the dermatology department for acute contact dermatitis due to NSO and had patch tests performed. Main Outcomes and Measures Clinical and histologic features of the cutaneous eruptions, length of hospital stay, chemical analysis of NSO, and results of patch tests. Results Three patients (3 women; median age, 27 years [range, 20-47 years]) were included in the case series. All patients had polymorphic skin lesions spreading beyond the area of NSO application: typical and atypical targets, patches with central blisters, erythematous or purpuric plaques with a positive Nikolsky sign mimicking Stevens-Johnson syndrome, or toxic epidermal necrolysis. Two patients had pustules. They had severe impairment, with more than 15% skin detachment and fever. The results of skin biopsies showed epidermal apoptosis characterized by vacuolar alteration of the basal layer, keratinocyte apoptosis, and a moderate perivascular infiltrate of lymphocytes in the dermis. The results of patch tests using the patients' NSO were all positive. The results of gas chromatography combined with mass spectrometry performed on the NSO of 1 patient identified several constituent substances, mainly terpenes, thymoquinone, linoleic acid, and fatty acids. Conclusions and Relevance These cases suggest that acute contact dermatitis due to NSO may induce topically triggered epidermal apoptosis, previously described as the concept of acute syndrome of apoptotic pan epidermolysis. Thymoquinone and p-cymene may be the main agents involved in the pathophysiologic characteristics of this acute contact dermatitis. Clinicians should be aware of such severe reactions to NSO and report these cases to pharmacovigilance authorities.
Collapse
Affiliation(s)
- Olivier Gaudin
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Feyrouz Toukal
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Camille Hua
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Nicolas Ortonne
- Pathology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Haudrey Assier
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Arnaud Jannic
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Elena Giménez-Arnau
- National Center for Research, Mixed Research Unit 7177, University of Strasbourg, Strasbourg, France
| | - Pierre Wolkenstein
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,University of Paris Est Créteil Val de Marne, Université Paris-Est Créteil, Créteil, France.,Reference Center for Severe Cutaneous Adverse Reactions, Créteil, France.,Equipe d'Accueil 7379, Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Créteil, France
| | - Olivier Chosidow
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,University of Paris Est Créteil Val de Marne, Université Paris-Est Créteil, Créteil, France.,Reference Center for Severe Cutaneous Adverse Reactions, Créteil, France.,Equipe d'Accueil 7379, Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, Assistance publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Reference Center for Severe Cutaneous Adverse Reactions, Créteil, France.,Equipe d'Accueil 7379, Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Créteil, France
| |
Collapse
|
111
|
Deschamps O, Ortonne N, Hüe S, Rodriguez C, Deschodt C, Hirsch G, Colin A, Grégoire L, Delfau-Larue MH, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S. Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. Br J Dermatol 2019; 182:355-363. [PMID: 31127953 DOI: 10.1111/bjd.18166] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/07/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND Acute exanthemas (AEs) are frequently seen; they can be caused by drugs or viruses but often the cause is unknown. OBJECTIVES To describe the clinical, virological and histological aspects of AEs and explore their cytokinic and metagenomic profiles. METHODS This prospective study examined 98 patients with AE, from February to July 2014. Clinical data were recorded in a standardized chart. Virological investigation and skin biopsies were performed. In addition, blood and skin samples were analysed for cytokines and then by a shotgun metagenomic approach. We identified five groups of patients: those with maculopapular exanthemas (MPEs) that were virally induced (group 1); those with drug-induced MPEs (group 2), those with MPEs that were both viral and drug induced (group 3), those with idiopathic MPEs (group 4) and those with pityriasis rosea (group 5). RESULTS A virus was identified in 29 cases (human herpesvirus 6, 72%). Cytokinic analysis of the skin (n = 23 MPEs) showed higher levels of interferon-γ and interleukin-1 receptor-α in viral MPEs, higher interleukin-33 levels in idiopathic MPEs, and higher macrophage inflammatory protein 1α levels in drug-induced MPEs. By metagenomics analysis (n = 10 MPEs), viruses identified with routine practice methods were not found in group 1 (n = 4 MPEs). However, Enterovirus A was detected in two cases, especially in a group 1 patient for whom metagenomic analysis rectified the diagnosis of the culprit agent. CONCLUSIONS Human herpesvirus 6 was the virus most frequently identified, and histology did not discriminate MPEs. In addition, the level of interleukin-33 seen in idiopathic MPEs suggests that an environmental factor may be the trigger for these. The results bring into question the utility of routine polymerase chain reaction analysis and viral serology for determining cause in AE. What's already known about this topic? Acute exanthemas, especially maculopapular exanthemas, are a frequent reason for patients consulting emergency and dermatology departments. It is difficult to evaluate the aetiology of acute exanthema based on the clinical aspects. Few data are available on the investigations needed in routine practice, and no prospective series have been published. What does this study add? Our study provides a global and prospective description of acute exanthemas. Cytokine analysis could help to investigate the pathophysiology of idiopathic eruptions. Metagenomic analysis provides new insights about the value of routine practice virological investigations. We show for the first time the feasibility of metagenomics analysis in the skin, which results question the interest of routine PCR and viral sérologies for the exploration of such acute exanthemas.
Collapse
Affiliation(s)
- O Deschamps
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - N Ortonne
- Department of Pathology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France
| | - S Hüe
- EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France.,Department of Immunology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - C Rodriguez
- EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France.,Department of Virology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - C Deschodt
- Department of Virology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - G Hirsch
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - A Colin
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - L Grégoire
- Clinical Research Unit, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - M-H Delfau-Larue
- EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France.,Department of Immunology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - O Chosidow
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France
| | - P Wolkenstein
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France.,Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil Val de Marne, Créteil, France.,Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| |
Collapse
|
112
|
Lecadet A, Woerther PL, Hua C, Colin A, Gomart C, Decousser JW, Mekontso Dessap A, Wolkenstein P, Chosidow O, de Prost N, Ingen-Housz-Oro S. Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases. J Am Acad Dermatol 2019; 81:342-347. [DOI: 10.1016/j.jaad.2019.03.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 03/11/2019] [Accepted: 03/13/2019] [Indexed: 12/17/2022]
|
113
|
Lalevée S, Audureau E, Riou A, Colin A, Anquetin M, Barau C, Valeyrie-Allanore L, Delfau-Larue MH, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S, Hüe S. Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns. Clin Exp Allergy 2019; 49:1258-1261. [PMID: 31206897 DOI: 10.1111/cea.13449] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Revised: 05/14/2019] [Accepted: 05/30/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Sophie Lalevée
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Etienne Audureau
- Public Health Department, AP-HP, Henri Mondor Hospital, and A-TVB DHU, CEpiA (Clinical Epidemiology and Aging) Unit EA7376, UPEC, Créteil, France.,University Paris Est-Créteil UPEC, Créteil, France
| | - Audrey Riou
- Biological Immunology and Haematology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Audrey Colin
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Maxime Anquetin
- Biological Ressources Platform, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Caroline Barau
- Biological Ressources Platform, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Laurence Valeyrie-Allanore
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Marie-Hélène Delfau-Larue
- University Paris Est-Créteil UPEC, Créteil, France.,Biological Immunology and Haematology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,University Paris Est-Créteil UPEC, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Pierre Wolkenstein
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,University Paris Est-Créteil UPEC, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,University Paris Est-Créteil UPEC, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Sophie Hüe
- University Paris Est-Créteil UPEC, Créteil, France.,Biological Immunology and Haematology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions, AP-HP, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
114
|
Sanchez J, Ingen-Housz-Oro S, Chosidow O, Antonicelli F, Bernard P. Rituximab as Single Long-term Maintenance Therapy in Patients With Difficult-to-Treat Pemphigus. JAMA Dermatol 2019; 154:363-365. [PMID: 29299590 DOI: 10.1001/jamadermatol.2017.5176] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Julia Sanchez
- Department of Dermatology, Reims University Hospital, Reims, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique des Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Epidemiology in Dermatology and Evaluation of Therapeutics, Unit 7379, University Paris Est, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, Assistance Publique des Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Epidemiology in Dermatology and Evaluation of Therapeutics, Unit 7379, University Paris Est, Créteil, France
| | - Frank Antonicelli
- Laboratory of Dermatology, Unit 7319, University of Reims Champagne-Ardenne, Reims, France
| | - Philippe Bernard
- Department of Dermatology, Reims University Hospital, Reims, France.,Laboratory of Dermatology, Unit 7319, University of Reims Champagne-Ardenne, Reims, France
| |
Collapse
|
115
|
Canouï E, Ingen-Housz-Oro S, Ortonne N, Lebeaux D, Rodriguez-Nava V, Godeau B, Mahévas M. [Hemophagocytic lymphohistiocytosis with granulomatosis and diffuse T-cell infiltration associated with disseminated Nocardiosis and pulmonary infection due to Streptomyces spp]. Rev Med Interne 2019; 40:457-461. [PMID: 31103241 DOI: 10.1016/j.revmed.2019.04.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Revised: 04/11/2019] [Accepted: 04/24/2019] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome frequently secondary to infectious disease, especially in immuno-compromised patients. We report a HLH secondary to disseminated nocardiosis and Streptomyces spp pulmonary infection. CASE REPORT A 69-years-old women had recent subcutaneous nodules of the forearms and loins associated with peripheral neuropathy and pulmonary nodule of the right upper lobe. Cutaneous biopsy revealed granuloma. Cutaneous lesions worsened and the patient developed a HLH with probable cardiac and neurological involvement, associated with cutaneous granulomatosis and diffuse polyclonal lymphocyte proliferation. Nocardia PCR was positive in cutaneous biopsy. Pulmonary samples revealed Streptomyces in culture and Nocardia in PCR. The evolution under antibiotic treatment was favorable. CONCLUSION Recent diagnosis of HLH without obvious etiology should lead to etiological investigation, including the search for infections with slow-growing bacteria such as Nocardia or Streptomyces spp.
Collapse
Affiliation(s)
- E Canouï
- Service de médecine interne, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94010 Créteil, France
| | - N Ortonne
- Service d'anatomo-pathologie, hôpital Henri-Mondor, AP-HP, 94010 Créteil, France
| | - D Lebeaux
- Service de microbiologie, unité mobile de microbiologie clinique, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - V Rodriguez-Nava
- UMR 5557, université de Lyon, université de Lyon 1, Research group on bacterial opportunistic pathogens and environment, écologie microbienne, French observatory of nocardiosis, CNRS, VetAgro Sup, Northern Hospital Group, hospices civils de Lyon, 69317 Lyon, France
| | - B Godeau
- Service de médecine interne, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - M Mahévas
- Service de médecine interne, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| |
Collapse
|
116
|
Chaby G, Ingen-Housz-Oro S, De Prost N, Wolkenstein P, Chosidow O, Fardet L. Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. J Am Acad Dermatol 2019; 80:1453-1455. [DOI: 10.1016/j.jaad.2018.10.058] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 10/25/2018] [Accepted: 10/28/2018] [Indexed: 11/28/2022]
|
117
|
Chaby G, Lebrun-Vignes B, Haddad C, Hemery F, Ingen-Housz-Oro S, de Prost N, Wolkenstein P, Chosidow O, Fardet L. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. J Allergy Clin Immunol Pract 2019; 7:1344-1346. [PMID: 30292922 DOI: 10.1016/j.jaip.2018.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 09/20/2018] [Accepted: 09/21/2018] [Indexed: 06/08/2023]
Affiliation(s)
- Guillaume Chaby
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.
| | - Bénédicte Lebrun-Vignes
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France; Department of Pharmacovigilance, Hôpital Pitié-Salpétrière, AP-HP, Paris, France
| | - Cynthia Haddad
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France
| | - Francois Hemery
- Department of Medical Informatics, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - Saskia Ingen-Housz-Oro
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France; Department of Dermatology and Reference Center for Toxic Bullous Diseases, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - Nicolas de Prost
- Department of Intensive Care, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - Pierre Wolkenstein
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France; Department of Dermatology and Reference Center for Toxic Bullous Diseases, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - Olivier Chosidow
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France; Department of Dermatology and Reference Center for Toxic Bullous Diseases, Hôpital Henri-Mondor, AP-HP, Créteil, France; INSERM, Centre d'Investigation Clinique 1430, Créteil, France
| | - Laurence Fardet
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France; Department of Dermatology and Reference Center for Toxic Bullous Diseases, Hôpital Henri-Mondor, AP-HP, Créteil, France
| |
Collapse
|
118
|
Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Caux F, Bernard P, Bedane C, Alexandre M, Dereure O, Quereux G, Le Bidre E, Plée J, Picard-Dahan C, Le Roux-Villet C, Duvert-Lehembre S, Richard MA, Delaporte E, Debarbieux S, Jullien D, D'Incan M, Konstantinou MP, Bouaziz JD, Tancrède-Bohin E, Doutre MS, Bourgault Villada I, Cordel N, Sassolas B, Viguier MA, Mellottée B, Jouen F, Hebert V, Joly P. [Update of the French recommendations for the management of pemphigus]. Ann Dermatol Venereol 2019; 146:279-286. [PMID: 30929874 DOI: 10.1016/j.annder.2019.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 11/24/2018] [Accepted: 01/23/2019] [Indexed: 01/29/2023]
Affiliation(s)
- L Jelti
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France.
| | - C Prost-Squarcioni
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France
| | - F Caux
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Bedane
- Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France
| | - M Alexandre
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - O Dereure
- Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France
| | - G Quereux
- Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France
| | - E Le Bidre
- Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France
| | - J Plée
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - C Picard-Dahan
- Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France
| | - C Le Roux-Villet
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - S Duvert-Lehembre
- Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France
| | - M-A Richard
- EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - E Delaporte
- Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France
| | - S Debarbieux
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France
| | - M D'Incan
- Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France
| | - M-P Konstantinou
- Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France
| | - J-D Bouaziz
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - E Tancrède-Bohin
- Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M-S Doutre
- Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France
| | - I Bourgault Villada
- Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France
| | - N Cordel
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe
| | - B Sassolas
- Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France
| | - M-A Viguier
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France
| | - B Mellottée
- Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - F Jouen
- Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | - V Hebert
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | - P Joly
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| | -
- Service de dermatologie, Inserm U1234, université de Normandie, CHU de Rouen, 1 rue de Germont, 76000 Rouen, France; Service de dermatologie, université Paris 13, hôpital Avicenne, AP-HP, 93000 Bobigny, France; Service de dermatologie, hôpital Henri-Mondor, AP-HP, 94000 Créteil, France; Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 51092 Reims, France; Service de dermatologie, hôpital Dupuytren, 87042 Limoges, France; Service de dermatologie, Inserm U1058, université de Montpellier, hôpital St-Eloi, 34295 Montpellier, France; Service de dermatologie, CHU Hôtel-Dieu, 44093 Nantes, France; Service de dermatologie, hôpital Trousseau, CHRU de Tours, 37044 Tours, France; Service de dermatologie, hôpital Bichat-Claude-Bernard, AP-HP, 75018 Paris, France; Service de dermatologie, hôpital Claude-Huriez, CHRU de Lille, 59037 Lille, France; EA3279 : CEReSS-centre d'étude et de recherche sur les services de santé et la qualité de vie, service de dermatologie, université Aix-Marseille, hôpital de La Timone, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, université Aix-Marseille, hôpital Nord, Assistance publique-Hôpitaux de Marseille, 13385 Marseille, France; Service de dermatologie, hôpital Edouard-Herriot, hospices civils de Lyon, 69437 Lyon, France; Service de dermatologie, CHU Estaing, 63000 Clermont-Ferrand, France; Service de dermatologie, hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Service de dermatologie, hôpital Ambroise-Paré, AP-HP, 92100 Boulogne-Billancourt, France; Unité de dermatologie-immunologie clinique, CHU de Guadeloupe, 97159 Pointe-à-Pitre cedex, Guadeloupe; Service de médecine interne et pneumologie, hôpital de la Cavale-Blanche, CHRU de Brest, 29609 Brest, France; Inserm U1234, laboratoire d'immunologie, université de Normandie, CHU de Rouen, 76000 Rouen, France
| |
Collapse
|
119
|
Ingen-Housz-Oro S, Assier H, Gener G, Milpied B, Soria A, Bernier C, Descamps V, Tetart F, Staumont-Sallé D, Valeyrie-Allanore L, Valois A, Sassolas B, Bensaid B, Lebrun-Vignes B, Barbaud A. [Delayed hypersensitivity to anti-tuberculosis drugs. Proposed practical management plan for exanthema: when to stop, which allergological investigations to perform, and how to restart treatment]. Ann Dermatol Venereol 2019; 146:313-318. [PMID: 30904277 DOI: 10.1016/j.annder.2019.01.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 10/06/2018] [Accepted: 01/15/2019] [Indexed: 12/20/2022]
Affiliation(s)
- S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France.
| | - H Assier
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - G Gener
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - B Milpied
- Service de dermatologie, hôpital Saint-André, 1, rue Jean-Burguet, 33000 Bordeaux, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - A Soria
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - C Bernier
- Service de dermatologie, CHU Hôtel-Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - V Descamps
- Service de dermatologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - F Tetart
- Service de dermatologie, CHU Charles-Nicolle, 1, rue De Germont, 76100 Rouen, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - D Staumont-Sallé
- Service de dermatologie, CHRU Claude-Huriez, rue Michel-Polonovski, 59000 Lille, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - L Valeyrie-Allanore
- Cabinet de dermatologie, 18, avenue Quihou, 94160 Saint-Mandé, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - A Valois
- Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, 2, boulevard Sainte-Anne, 83800 Toulon cedex 9, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - B Sassolas
- Service de médecine interne, hôpital Cavale-Blanche, CHRU de Brest, boulevard Tanguy Prigent, 29600 Brest, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - B Bensaid
- Service de dermatologie, hôpital Edouard-Herriot, 5, place D'Arsonval, 69003 Lyon, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - B Lebrun-Vignes
- Département de pharmacovigilance, hôpital La Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | - A Barbaud
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| | -
- Groupe FISARD (groupe Toxidermies) de la Société française de dermatologie, 10, cité Malesherbes, 75009 Paris, France
| |
Collapse
|
120
|
de Risi-Pugliese T, Sbidian E, Ingen-Housz-Oro S, Le Cleach L. Interventions for erythema multiforme: a systematic review. J Eur Acad Dermatol Venereol 2019; 33:842-849. [PMID: 30680804 DOI: 10.1111/jdv.15447] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 12/19/2018] [Indexed: 11/28/2022]
Abstract
Treatment of erythema multiforme (EM) is not codified. We performed a systematic review of the effect of any topical or systemic treatment on time to healing and frequency of episodes with acute and chronic forms of EM in adults. Four databases (MEDLINE, CENTRAL, EMBASE and LILACS) and other sources were searched for articles published up to 20 March 2018. Randomized control trials (RCTs), observational studies and case series (n ≥ 10) were considered. From 1558 references, we included one RCT and six case series. The RCT (n = 20) showed a significant difference in complete remission of EM with continuous acyclovir vs. placebo over 6 months. One case series found a mean reduction in flare duration with thalidomide for recurrent EM (5.1 vs. 16.2 days; n = 20). Adverse events were poorly or not reported in included studies. Quality of life was never assessed. One limitation of our study is that we excluded the cases of isolated mucosal EM in order to prevent inclusion of Stevens-Johnson syndrome cases. In conclusion, there is low-level evidence for continuous acyclovir treatment for recurrent EM (one RCT). Evidence for other treatments is only based on retrospective case series. Results for thalidomide, in particular, encourage further research. Data concerning safety are insufficient. PROSPERO registration no. CRD42016053175.
Collapse
Affiliation(s)
- T de Risi-Pugliese
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Service de Dermatologie et Allergologie, AP-HP, Hôpital Tenon, Paris, France
| | - E Sbidian
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EA 7379 EpiDermE (Epidemiology in Dermatology and Evaluation of Therapeutics), Créteil, France.,INSERM CIC 1430, Paris-Est Creteil University, Creteil, France
| | - S Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EA 7379 EpiDermE (Epidemiology in Dermatology and Evaluation of Therapeutics), Créteil, France
| | - L Le Cleach
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EA 7379 EpiDermE (Epidemiology in Dermatology and Evaluation of Therapeutics), Créteil, France
| |
Collapse
|
121
|
Thorel D, Delcampe A, Ingen-Housz-Oro S, Hajj C, Gabison E, Chosidow O, Wolkenstein P, Royer G, Ezzedine K, Muraine M, Gueudry J. Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2019; 181:212-213. [PMID: 30633324 DOI: 10.1111/bjd.17627] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- D Thorel
- Department of Ophthalmology, Charles Nicolle University Hospital, Rouen, France
| | - A Delcampe
- Department of Ophthalmology, Charles Nicolle University Hospital, Rouen, France.,Department of Ophthalmology, Bichat Claude Bernard Hospital, Paris, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| | - S Ingen-Housz-Oro
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - C Hajj
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Gabison
- Department of Ophthalmology, Bichat Claude Bernard Hospital, Paris, France
| | - O Chosidow
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - P Wolkenstein
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - G Royer
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - K Ezzedine
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - M Muraine
- Department of Ophthalmology, Charles Nicolle University Hospital, Rouen, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| | - J Gueudry
- Department of Ophthalmology, Charles Nicolle University Hospital, Rouen, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| |
Collapse
|
122
|
Garel B, Ingen-Housz-Oro S, Afriat D, Prost-Squarcioni C, Tétart F, Bensaid B, Bara Passot C, Beylot-Barry M, Descamps V, Duvert-Lehembre S, Grootenboer-Mignot S, Jeudy G, Soria A, Valnet-Rabier MB, Barbaud A, Caux F, Lebrun-Vignes B. Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol 2019; 85:570-579. [PMID: 30511379 DOI: 10.1111/bcp.13827] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Revised: 11/08/2018] [Accepted: 11/23/2018] [Indexed: 11/27/2022] Open
Abstract
AIMS Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. METHODS Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. RESULTS Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. CONCLUSIONS There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
Collapse
Affiliation(s)
- Bethsabée Garel
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France.,EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.,Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France
| | - Daniele Afriat
- Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France
| | - Catherine Prost-Squarcioni
- Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Pathology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - Florence Tétart
- Department of Dermatology, Rouen University Hospital, Rouen, France
| | - Benoit Bensaid
- Drug Allergy Unit-CCR2A, Department of Allergy and Clinical Immunology, CHU Lyon-Sud, Pierre Benite, France
| | | | - Marie Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Vincent Descamps
- Department of Dermatology, APHP, Bichat Claude Bernard Hospital, Paris Diderot University
| | | | | | - Géraldine Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Angèle Soria
- Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.,Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France.,Inserm, UMR 1135, Paris, France
| | | | - Annick Barbaud
- Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.,Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.,Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France
| | - Frédéric Caux
- Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - Bénédicte Lebrun-Vignes
- EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.,Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.,Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France
| |
Collapse
|
123
|
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019; 139:31-37. [DOI: 10.1016/j.jid.2018.04.042] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 11/29/2022]
|
124
|
Bontoux C, De Masson A, Boccara O, Bodemer C, Fraitag S, Balme B, Franck N, Carlotti A, Comoz F, Verneuil L, Brasme JF, Duplan M, Croué A, Templier I, Beltraminelli H, Dereure O, Szablewski V, Thevenin C, Boulinguez S, Viraben R, Tournier E, Lamant L, Ortonne N, Ingen-Housz-Oro S, Beckerich F, Grange F, Durlach A, Amatore F, Frouin E, McIntyre E, Asnafi V, Kim R, Clappier E, Soulier J, Boissel N, Dombret H, Bagot M, Battistella M. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30538-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
125
|
Plaquevent M, Tétart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, Hebert V, Roussel A, Avenel-Audran M, Chaby G, D'Incan M, Ferrier-Le-Bouedec MC, Duvert-Lehembre S, Picard-Dahan C, Jeudy G, Collet E, Labeille B, Morice C, Richard MA, Bourgault-Villada I, Litrowski N, Bara C, Mahe E, Prost-Squarcioni C, Alexandre M, Quereux G, Bernier C, Soria A, Thomas-Beaulieu D, Pauwels C, Dereure O, Benichou J, Joly P. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J Invest Dermatol 2018; 139:835-841. [PMID: 30543900 DOI: 10.1016/j.jid.2018.10.045] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 10/17/2018] [Accepted: 10/29/2018] [Indexed: 12/13/2022]
Abstract
Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. The observed frequencies of intake of the whole gliptin class and that of vildagliptin in the BP population were higher than those in the general population after age standardization (whole gliptin class: 6.0%; 95% confidence interval = 4.9-7.1% vs. 3.6%, observed-to-expected drug intake ratio = 1.7; 95% confidence interval = 1.4-2.0; P < 0.0001; vildagliptin = 3.3%; 95% confidence interval = 2.5-4.1% vs. 0.7%, ratio = 4.4; 95% confidence interval = 3.5-5.7; P < 0.0001). The association of any gliptin+metformin was also higher than in the general population, ratio = 1.8 (95% confidence interval = 1.3-2.4; P < 0.0001). Gliptin-associated BP had no specific clinical characteristics. Gliptin was stopped in 48 (45.3%) cases. Median duration to achieve disease control, rate, and delay of relapse were not different whether gliptin was stopped or continued. This study strongly supports the association between gliptin intake, particularly vildagliptin, and the onset of BP.
Collapse
Affiliation(s)
- Marthe Plaquevent
- Department of Dermatology, Rouen University Hospital and Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, France.
| | - Florence Tétart
- Department of Dermatology, Rouen University Hospital and Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, France
| | - Laurence Fardet
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Laurence Valeyrie-Allanore
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | | | - Vivien Hebert
- Department of Dermatology, Rouen University Hospital and Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, France
| | - Aude Roussel
- Department of Dermatology, Orleans Hospital, Orléans, France
| | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Michel D'Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | | | | | - Geraldine Jeudy
- Department of Dermatology Dijon University Hospital, Dijon, France
| | - Evelyne Collet
- Department of Dermatology Dijon University Hospital, Dijon, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint Etienne, Saint Etienne, France
| | - Cécile Morice
- Department of Dermatology, University of Caen, Caen, France
| | - Marie-Aleth Richard
- Department of Dermatology, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Unité Mixte de Recherche 911, Institut National de la Santé et de la Recherche Médicale CRO2, Marseille, France
| | | | - Noémie Litrowski
- Department of Dermatology, Jacques Monod Hospital, Montivilliers, France
| | - Corina Bara
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Emmanuel Mahe
- Department of Dermatology, Argenteuil Hospital, Argenteuil, France
| | | | - Marina Alexandre
- Department of Dermatology, University of Paris XIII, Bobigny, France
| | - Gaelle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Claire Bernier
- Department of Dermatology, University of Nantes, Nantes, France
| | - Angèle Soria
- Department of Dermatology and Allergology, Tenon Hospital, Paris, France
| | | | - Christine Pauwels
- Department of Dermatology, Poissy-Saint Germain Hospital, Saint-Germain-en-Laye, France
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Jacques Benichou
- Department of Biostatistics, Rouen University Hospital and Institut National de la Santé et de la Recherche Médicale U1219, Normandie University, Rouen, France
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital and Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, France
| | | | | |
Collapse
|
126
|
El Khoury M, Assier H, Gener G, Paul M, Haddad C, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S. Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. Br J Dermatol 2018; 179:978-979. [DOI: 10.1111/bjd.16738] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- M. El Khoury
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
| | - H. Assier
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
- Referral Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions; Créteil France
| | - G. Gener
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
- Referral Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions; Créteil France
| | - M. Paul
- Department of Pharmacy; AP-HP; Henri Mondor Hospital; Créteil France
| | - C. Haddad
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
| | - O. Chosidow
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
- Referral Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions; Créteil France
- EA7379 EpidermE; UPEC; Créteil France
- Université Paris Est Créteil Val de Marne UPEC; Créteil France
| | - P. Wolkenstein
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
- Referral Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions; Créteil France
- EA7379 EpidermE; UPEC; Créteil France
- Université Paris Est Créteil Val de Marne UPEC; Créteil France
| | - S. Ingen-Housz-Oro
- Department of Dermatology; AP-HP; Henri Mondor Hospital; Créteil France
- Referral Center for Toxic Bullous Diseases and Severe Cutaneous Adverse Reactions; Créteil France
- EA7379 EpidermE; UPEC; Créteil France
| |
Collapse
|
127
|
Urbina T, Hua C, Sbidian E, Ingen-Housz-Oro S, Duong TA, Wolkenstein P, Bosc R, Razazi K, Carteaux G, Chosidow O, Mekontso Dessap A, de Prost N. Urgences dermatologiques en réanimation : infections nécrosantes de la peau et des parties molles et toxidermies graves. Méd Intensive Réa 2018. [DOI: 10.3166/rea-2018-0064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Les urgences dermatologiques nécessitant une admission en réanimation sont rares mais associées à une mortalité élevée et à de lourdes séquelles à long terme. Elles sont essentiellement représentées par les infections nécrosantes des tissus mous (également appelées : dermohypodermites bactériennes nécrosantes-fasciites nécrosantes [DHBN-FN]) et par les toxidermies graves que sont les nécrolyses épidermiques (comprenant le syndrome de Lyell ou nécrolyse épidermique toxique [NET], le syndrome de Stevens-Johnson [SJS] et le DRESS (drug reaction with eosinophilia and systemic symptoms)). Elles ont pour caractéristiques communes un diagnostic souvent difficile, la nécessité d’une approche multidisciplinaire et de soins paramédicaux lourds et spécifiques, imposant fréquemment le transfert dans un centre expert. Le traitement des DHBN-FN est médicochirurgical, associant un débridement chirurgical précoce et une antibiothérapie probabiliste à large spectre. La présence de signes de gravité locaux (nécrose, crépitation, douleur intense) ou généraux (sepsis, choc septique) est une indication d’urgence à l’exploration chirurgicale. Sa précocité est le principal facteur pronostique modifiable, les recommandations de thérapeutiques complémentaires (immunoglobulines intraveineuses, oxygénothérapie hyperbare, pansement à pressions négatives, ...) reposant à ce jour sur un faible niveau de preuve. L’élément essentiel de la prise en charge des toxidermies graves est la recherche et l’arrêt du médicament imputable, facteur essentiel du pronostic. Le SJS et le NET, en général associés à une ou plusieurs atteintes muqueuses, entraînent dans les formes les plus graves une défaillance cutanée aiguë. La prise en charge repose sur les soins de support (correction des troubles hydroélectrolytiques, prévention de l’hypothermie, prévention et traitement des épisodes infectieux, analgésie et anxiolyse, soins locaux). Les complications infectieuses et respiratoires sont les principales causes de décès à la phase aiguë. Aucun traitement spécifique n’a fait la preuve de son efficacité à ce jour. Le diagnostic de DRESS est difficile, et la prise en charge doit être multidisciplinaire. Sa gravité tient aux possibles atteintes viscérales associées (hépatique, rénale et cardiaque) qui justifient dans les formes graves d’une corticothérapie urgente.
Collapse
|
128
|
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. J Invest Dermatol 2018; 138:1982-1989. [DOI: 10.1016/j.jid.2018.03.1516] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 02/23/2018] [Accepted: 03/12/2018] [Indexed: 12/17/2022]
|
129
|
Dridi SM, Bellakhdar F, Ortonne N, Bayet K, Ingen-Housz-Oro S, Gaultier F. [Autoimmune bullous diseases with gingival expression: A proposed non-iatrogenic gingival biopsy technique]. Ann Dermatol Venereol 2018; 145:572-577. [PMID: 30143321 DOI: 10.1016/j.annder.2018.06.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 05/20/2018] [Accepted: 06/18/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Gingival expression of autoimmune bullous diseases (AIBD) may be inaugural, exclusive or dominant (mucous membrane pemphigoid, pemphigus vulgaris). Histology and direct immunofluorescence are essential to diagnosis. The location of the biopsy and the surgical technique determine the histological quality of the tissue sample. However, gingival tissue is often considered fragile and easily impaired during biopsy. We suggest an original biopsy protocol for the gingival papillae that is simple to perform, non-iatrogenic, and readily accessible to all practitioners who usually treat AIBD patients presenting isolated gingival expression (dermatologists, stomatologists, odontology specialists, ENT specialists). PATIENTS AND METHODS We conducted a retrospective study from 2012 to 2017 identifying all patients presenting AIBD with gingival expression for whom we performed papillary gingival biopsy for diagnostic ends. Our main objective was to determine the diagnostic efficacy and safety of this surgical technique. RESULTS Over the study period, 34 papillary gingival biopsies were taken from 19 patients : 15 for histopathological examination and 19 for direct immunofluorescence. Of the 34 biopsies, only one could not be properly analyzed due to lack of epithelium and a second tissue sample was therefore necessary. No short- or long-term complications occurred during post-operative follow-up. CONCLUSION Gingival papilla biopsy is perfectly suited to the histopathological and immunohistochemical examinations needed for diagnosis of AIBD with isolated gingival expression. This surgical technique shows great efficacy and very good safety. However, additional studies are necessary to confirm our preliminary results, in particular the absence of iatrogenic effects.
Collapse
Affiliation(s)
- S-M Dridi
- Médecine bucco-dentaire, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Pôle St Jean-d'Angély, laboratoire Micoralis (Microbiologie orale, immunothérapie et santé) EA-7354 UFR d'odontologie, 24, avenue des Diables-Bleus, 06357 Nice cedex 4, France.
| | - F Bellakhdar
- Médecine bucco-dentaire, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - N Ortonne
- Anatomopathologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - K Bayet
- Chirurgie orale, hôpital Henri-Mondor, faculté d'odontologie Paris Descartes, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, centre de compétence des maladies bulleuses auto-immunes Malibul, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - F Gaultier
- Chirurgie orale, hôpital Henri-Mondor, faculté d'odontologie Paris Descartes, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| |
Collapse
|
130
|
Kechichian E, Ingen-Housz-Oro S, Sbidian E, Hemery F, Bernier C, Fite C, Delaunay J, Staumont-Sallé D, Toukal F, Dupin N, Abasq C, Samimi M, Picard C, Hebert V, Prost C, Monfort JB, Milpied B, Wolkenstein P, Chosidow O. A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. Br J Dermatol 2018; 179:1009-1011. [DOI: 10.1111/bjd.16928] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- E. Kechichian
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
| | - S. Ingen-Housz-Oro
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
| | - E. Sbidian
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| | - F. Hemery
- Department of Medical Information; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
| | - C. Bernier
- Department of Dermatology; CHU Nantes; Nantes France
| | - C. Fite
- Department of Dermatology; APHP, Hôpital Bichat; Paris France
| | - J. Delaunay
- Department of Dermatology; CHU Angers; Angers France
| | - D. Staumont-Sallé
- Department of Dermatology; Hôpital Claude Huriez - CHRU Lille; Lille France
| | - F. Toukal
- Department of Dermatology; Hôpital Saint André Bordeaux; Bordeaux France
| | - N. Dupin
- Department of Dermatology; APHP, Hôpital Tarnier; Paris France
| | - C. Abasq
- Department of Dermatology; Department of Dermatology; CHU Brest; Brest France
| | - M. Samimi
- Department of Dermatology; CHU de Tours; Tours France
| | - C. Picard
- Department of Dermatology; CHU de Caen; Caen France
| | - V. Hebert
- Department of Dermatology; CHU de Rouen; Rouen France
| | - C. Prost
- Department of Dermatology; APHP, Hôpital Avicenne; Bobigny France
| | - J.-B. Monfort
- Department of Dermatology; APHP, Hôpital Tenon; Paris France
| | - B. Milpied
- Department of Dermatology; Hôpital Saint André Bordeaux; Bordeaux France
| | - P. Wolkenstein
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| | - O. Chosidow
- Department of Dermatology; APHP; Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny; 94010 Créteil France
- Department of Dermatology; EA 7379 - EpiDermE, Université Paris Est; Créteil France
- Department of Dermatology; Université Paris Est UPEC; Créteil France
| |
Collapse
|
131
|
Merlant M, Seta V, Bernard P, Fourati S, Meritet JF, Wolkenstein P, Dupin N, Joly P, Chosidow O, Ingen-Housz-Oro S. [Pemphigus and herpes: Multicentre survey and literature review]. Ann Dermatol Venereol 2018; 145:477-485. [PMID: 29866471 DOI: 10.1016/j.annder.2018.03.169] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2017] [Revised: 12/10/2017] [Accepted: 03/16/2018] [Indexed: 01/17/2023]
Abstract
BACKGROUND Although herpes superinfection is a well-known complication of pemphigus, it has not been widely investigated. AIM To investigate the frequency and features of herpes infection in patients with ongoing pemphigus. PATIENTS AND METHODS We carried out a multicenter retrospective study between 2008 and 2016 in patients with newly diagnosed pemphigus presenting active herpes infection. Clinical, virological, immunological and therapeutic data were collated. We performed a literature review for pemphigus and herpes. RESULTS Among the 191 pemphigus patients, screening for herpes (PCR or culture) was carried out in 11 to 71 % of subjects, depending on the center in question. Twenty-four patients (12 women, mean age 58 years) presented at least one episode of herpes infection. The frequency of positivity ranged from 0 to 42 % by center. Twenty-one cases consisted of pemphigus vulgaris and infection occurred at a mucosal site in 19 patients. Herpes infection was identified at the time of diagnosis in 15 patients and 17 patients received no specific treatment for their pemphigus. The virus was identified using PCR in 23 cases. Ten patients subsequently received prophylactic treatment for herpes. The mean duration of follow-up was 36 months (0-89 months). Thirteen of the 24 patients had 23 relapses of pemphigus; PCR testing for herpes was performed 19 times and was positive in 6 cases (31.5 %). CONCLUSION Our study showed wide variation in the incidence of herpes superinfection in patients with pemphigus, reflecting the different screening approach at each center (being performed either routinely or only in the event of strong suspicion). The prognostic value of routine screening for herpes in patients with active pemphigus lesions remains to be demonstrated by further prospective investigations.
Collapse
Affiliation(s)
- M Merlant
- Service de dermatologie, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris (AP-HP), 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - V Seta
- Service de dermatologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris (AP-HP), pavillon Tarnier, 89, rue d'Assas, 75006 Paris, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, 1, avenue du Général-Koening, 51100 Reims, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France
| | - S Fourati
- Laboratoire de virologie, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris (AP-HP), 94010 Créteil, France
| | - J-F Meritet
- Laboratoire de virologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris (AP-HP), 89, rue d'Assas, 75006 Paris, France
| | - P Wolkenstein
- Service de dermatologie, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris (AP-HP), 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France; Université Paris Est Créteil Val-de-Marne, UPEC, 94010 Créteil, France
| | - N Dupin
- Service de dermatologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris (AP-HP), pavillon Tarnier, 89, rue d'Assas, 75006 Paris, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France
| | - P Joly
- Service de dermatologie, hôpital Charles-Nicolle, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France
| | - O Chosidow
- Service de dermatologie, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris (AP-HP), 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France; Université Paris Est Créteil Val-de-Marne, UPEC, 94010 Créteil, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris (AP-HP), 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des maladies bulleuses auto-immunes MALIBUL, 76000 Rouen France.
| |
Collapse
|
132
|
Poizeau F, Gaudin O, Le Cleach L, Duong TA, Hua C, Hotz C, Ingen-Housz-Oro S, Sbidian E, Zehou O, Colin A, de Prost N, Lebrun-Vignes B, Chosidow O, Wolkenstein P, Fardet L. Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients—Exposed/Unexposed and Propensity Score-Matched Analyses. J Invest Dermatol 2018; 138:1293-1300. [DOI: 10.1016/j.jid.2017.12.034] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2017] [Revised: 11/26/2017] [Accepted: 12/20/2017] [Indexed: 11/27/2022]
|
133
|
Ingen-Housz-Oro S, Duong TA, de Prost N, Colin A, Fardet L, Lebrun-Vignes B, Barbaud A, Chosidow O, Wolkenstein P. Traitement des toxidermies graves. Ann Dermatol Venereol 2018; 145:454-464. [DOI: 10.1016/j.annder.2018.02.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 01/13/2018] [Accepted: 02/14/2018] [Indexed: 12/17/2022]
|
134
|
Gaudin O, Seta V, Alexandre M, Bohelay G, Aucouturier F, Mignot-Grootenboer S, Ingen-Housz-Oro S, Bernardeschi C, Schneider P, Mellottee B, Caux F, Prost-Squarcioni C. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. Front Immunol 2018; 9:1030. [PMID: 29881377 PMCID: PMC5976795 DOI: 10.3389/fimmu.2018.01030] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 04/24/2018] [Indexed: 01/27/2023] Open
Abstract
Mucous membrane pemphigoids (MMPs) and bullous pemphigoid (BP) are autoimmune bullous diseases that share physiopathological features: both can result from autoantibodies directed against BP180 or BP230 antigens. An association has been reported between BP and intake of gliptins, which are dipeptidyl peptidase-IV inhibitors used to treat type 2 diabetes mellitus. Clinical and immunological differences have been reported between gliptin-induced BPs and classical BPs: mucosal involvement, non-inflammatory lesions, and target BP180 epitopes other than the NC16A domain. Those findings accorded gliptins extrinsic accountability in triggering MMP onset. Therefore, we examined gliptin intrinsic accountability in a cohort of 313 MMP patients. To do so, we (1) identified MMP patients with gliptin-treated (challenge) diabetes; (2) selected those whose interval between starting gliptin and MMP onset was suggestive or compatible with gliptin-induced MMP; (3) compared the follow-ups of patients who did not stop (no dechallenge), stopped (dechallenge) or repeated gliptin intake (rechallenge); (4) compared the clinical and immunological characteristics of suggestive-or-compatible-challenge patients to 121 never-gliptin-treated MMP patients serving as controls; and (5) individually scored gliptin accountability as the trigger of each patient's MMP using the World Health Organization-Uppsala Monitoring Center, Naranjo- and Begaud-scoring systems. 17 out of 24 gliptin-treated diabetic MMP patients had suggestive (≤12 weeks) or compatible challenges. Complete remission at 1 year of follow-up was more frequent in the 11 dechallenged patients. One rechallenged patient's MMP relapsed. These 17 gliptin-treated diabetic MMP patients differed significantly from the MMP controls by more cutaneous, less buccal, and less severe involvements and no direct immunofluorescence IgA labeling of the basement membrane zone. Multiple autoantibody-target antigens/epitopes (BP180-NC16A, BP180 mid- and C-terminal parts, integrin α6β4) could be detected, but not laminin 332. Last, among the 24 gliptin-treated diabetic MMP patients, five had high (I4-I3), 12 had low (I2-I1) and 7 had I0 Begaud intrinsic accountability scores. These results strongly suggest that gliptins are probably responsible for some MMPs. Consequently, gliptins should immediately be discontinued for patients with a positive accountability score. Moreover, pharmacovigilance centers should be notified of these events.
Collapse
Affiliation(s)
- Olivier Gaudin
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - Vannina Seta
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Cochin Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Université Paris Descartes, Paris, France
| | - Marina Alexandre
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - Gérôme Bohelay
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - Françoise Aucouturier
- Department of Immunology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Saint-Louis Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris, France
| | - Sabine Mignot-Grootenboer
- Department of Immunology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Bichat Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Henri-Mondor Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Créteil, France
| | - Céline Bernardeschi
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Cochin Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Université Paris Descartes, Paris, France
| | - Pierre Schneider
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Saint-Louis Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris, France
| | - Benoît Mellottee
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - Frédéric Caux
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| | - Catherine Prost-Squarcioni
- Department of Dermatology, Referral Center for Autoimmune Bullous Diseases (MALIBUL), Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
- Department of Histology, UFR Léonard de Vinci, Paris 13 University, Bobigny, France
- Department of Pathology, Avicenne Hospital, Assistance Publique Hôpitaux De Paris (AP-HP), Paris 13 University, Bobigny, France
| |
Collapse
|
135
|
Ingen-Housz-Oro S, Duong TA, Bensaid B, Bellon N, de Prost N, Lu D, Lebrun-Vignes B, Gueudry J, Bequignon E, Zaghbib K, Royer G, Colin A, Do-Pham G, Bodemer C, Ortonne N, Barbaud A, Fardet L, Chosidow O, Wolkenstein P. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis 2018; 13:56. [PMID: 29636107 PMCID: PMC5894129 DOI: 10.1186/s13023-018-0793-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2017] [Accepted: 03/22/2018] [Indexed: 12/18/2022] Open
Abstract
Epidermal necrolysis (EN) encompasses Stevens-Johnson syndrome (SJS, < 10% of the skin affected), Lyell syndrome (toxic epidermal necrolysis, TEN, with ≥30% of the skin affected) and an overlap syndrome (10 to 29% of the skin affected). These rare diseases are caused, in 85% of cases, by pharmacological treatments, with symptoms occurring 4 to 28 days after treatment initiation. Mortality is 20 to 25% during the acute phase, and almost all patients display disabling sequelae (mostly ocular impairment and psychological distress). The objective of this French national diagnosis and care protocol (protocole national de diagnostic et de soins; PNDS), based on a critical literature review and on a multidisciplinary expert consensus, is to provide health professionals with an explanation of the optimal management and care of patients with EN. This PNDS, written by the French National Reference Center for Toxic Bullous Dermatoses was updated in 2017 (https://www.has-sante.fr/portail/jcms/c_1012735/fr/necrolyse-epidermique-syndromes-de-stevens-johnson-et-de-lyell). The cornerstone of the management of these patients during the acute phase is an immediate withdrawal of the responsible drug, patient management in a dermatology department, intensive care or burn units used to dealing with this disease, supportive care and close monitoring, the prevention and treatment of infections, and a multidisciplinary approach to sequelae. Based on published data, it is not currently possible to recommend any specific immunomodulatory treatment. Only the culprit drug and chemically similar molecules must be lifelong contraindicated.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France. .,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France. .,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.
| | - Tu-Anh Duong
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| | - Benoit Bensaid
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, Edouard Herriot Hospital, Lyon, France
| | - Nathalia Bellon
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Necker Hospital, Paris, France
| | - Nicolas de Prost
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Dévy Lu
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| | - Bénédicte Lebrun-Vignes
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Pharmacovigilance Department, AP-HP, La Pitié Salpêtrière Hospital, Paris, France
| | - Julie Gueudry
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Ophthalmology Department, Charles Nicolle Hospital, Rouen, France
| | - Emilie Bequignon
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Ear Nose and Throat Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Karim Zaghbib
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Psychiatry Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Gérard Royer
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Audrey Colin
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France
| | - Giao Do-Pham
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - Christine Bodemer
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Necker Hospital, Paris, France
| | - Nicolas Ortonne
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Annick Barbaud
- French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,Dermatology Department, AP-HP, Tenon Hospital, Paris, France
| | - Laurence Fardet
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Olivier Chosidow
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Pierre Wolkenstein
- Dermatology Department, AP-HP, Henri Mondor Hospital, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France.,French National Reference Center for Toxic Bullous Dermatoses, Créteil, France.,EA7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.,Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | | |
Collapse
|
136
|
Drahy F, Ingen-Housz-Oro S, Grootenboer-Mignot S, Wolkenstein P, Chosidow O. Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. JAMA Dermatol 2018; 154:487-489. [DOI: 10.1001/jamadermatol.2017.5889] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Faustine Drahy
- Department of Dermatology, Assistance Publique–Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique–Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris–Est Créteil Val de Marne, Créteil, France
- Referral Center for Toxic Bullous Diseases, Créteil, France
| | | | - Pierre Wolkenstein
- Department of Dermatology, Assistance Publique–Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris–Est Créteil Val de Marne, Créteil, France
- Referral Center for Toxic Bullous Diseases, Créteil, France
- Université Paris–Est Créteil Val de Marne, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, Assistance Publique–Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris–Est Créteil Val de Marne, Créteil, France
- Referral Center for Toxic Bullous Diseases, Créteil, France
- Université Paris–Est Créteil Val de Marne, Créteil, France
| |
Collapse
|
137
|
Alexandre K, Ingen-Housz-Oro S, Versini M, Sailler L, Benhamou Y. Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11 cases and review of the literature. Eur J Intern Med 2018; 50:e23-e24. [PMID: 29198498 DOI: 10.1016/j.ejim.2017.11.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 11/23/2017] [Accepted: 11/28/2017] [Indexed: 11/27/2022]
Affiliation(s)
- K Alexandre
- Department of Infectious Disease, Rouen University Hospital, Rouen F-76031, France.
| | | | - M Versini
- Department of Internal Medicine, Archet Hospital, Nice, France
| | - L Sailler
- Department of Internal Medicine, Purpan University Hospital, Toulouse, France
| | - Y Benhamou
- Department of Internal Medicine, Rouen University Hospital, Rouen F-76031, France; Inserm, U1096, Rouen, F-76000, France
| |
Collapse
|
138
|
Dumas M, Hua C, Hotz C, Velter C, Duong TA, Maraffi T, Ortonne N, Hüe S, Fardet L, de Prost N, Wolkenstein P, Ingen-Housz-Oro S, Chosidow O. Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that 'toxic' epidermal necrolysis can be 'non-toxic'. J Eur Acad Dermatol Venereol 2018. [PMID: 29524279 DOI: 10.1111/jdv.14935] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- M Dumas
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - C Hua
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - C Hotz
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - C Velter
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - T A Duong
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - T Maraffi
- Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - N Ortonne
- Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de marne, UPEC, Créteil, France
| | - S Hüe
- Université Paris Est Créteil Val de marne, UPEC, Créteil, France.,Immunology Department, AP-HP, Henri Mondor hospital, Créteil, France
| | - L Fardet
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - N de Prost
- Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - P Wolkenstein
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de marne, UPEC, Créteil, France.,Referral Center for Severe Cutaneous Adverse Reactions, Créteil, France
| | - S Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Referral Center for Severe Cutaneous Adverse Reactions, Créteil, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de marne, UPEC, Créteil, France.,Referral Center for Severe Cutaneous Adverse Reactions, Créteil, France
| |
Collapse
|
139
|
Gest N, Ingen-Housz-Oro S, Gener G, Bellanger M, Henn A, Gallien S, Flateau C. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to ethambutol. Med Mal Infect 2018; 48:302-305. [PMID: 29602678 DOI: 10.1016/j.medmal.2018.03.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2017] [Revised: 12/21/2017] [Accepted: 03/01/2018] [Indexed: 12/17/2022]
Affiliation(s)
- N Gest
- Service d'immunologie clinique et maladies infectieuses, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - S Ingen-Housz-Oro
- Service de dermatologie et allergologie, hôpital Henri-Mondor, 94000 Créteil, France
| | - G Gener
- Service de dermatologie et allergologie, hôpital Henri-Mondor, 94000 Créteil, France
| | - M Bellanger
- Service d'immunologie clinique et maladies infectieuses, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - A Henn
- Service d'immunologie clinique et maladies infectieuses, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - S Gallien
- Service d'immunologie clinique et maladies infectieuses, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - C Flateau
- Service d'immunologie clinique et maladies infectieuses, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
| |
Collapse
|
140
|
Amode R, Ingen-Housz-Oro S, Ortonne N, Bounfour T, Pereyre S, Schlemmer F, Bequignon E, Royer G, Wolkenstein P, Chosidow O. Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol 2018; 79:110-117. [PMID: 29559400 DOI: 10.1016/j.jaad.2018.03.013] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Revised: 03/03/2018] [Accepted: 03/09/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Mycoplasma pneumoniae infection has been documented in erythema multiforme (EM) and Stevens-Johnson syndrome-toxic epidermal necrosis (SJS-TEN). Clinical aspects of M pneumoniae-related EM have been poorly described in the literature. OBJECTIVE To highlight differences between M pneumoniae EM and non-M pneumoniae EM. METHODS This single-center, retrospective cohort study included all patients admitted to our dermatology department for EM during 2000-2015. We compared epidemiologic, clinical, and histologic data and follow-up for M pneumoniae EM and non-M pneumoniae EM cases. RESULTS Thirty-three patients with M pneumoniae EM were compared with 100 patients with non-M pneumoniae EM. Disease onset in winter was more frequent with M pneumoniae EM (P = .003). Acrally distributed lesions (32% vs 88%, P < .0001) and typical targets (45% vs 74%, P = .01) were less common in M pneumoniae EM than non-M pneumoniae EM. Multiple (≥2) mucousal membrane involvement was more frequent in M pneumoniae EM than non-M pneumoniae EM (97% vs 60%; P < .0001), as were mucosal and respiratory tract sequelae (P < .05). The mean hospital stay was longer with M pneumoniae EM patients: 9.5 days versus 5.1 days (P = .0002). A TEN-like pattern was observed in all 14 (100%) M pneumoniae EM skin biopsies versus 10 of 27 (48%) non-M pneumoniae EM biopsies (P < .001). LIMITATIONS The retrospective design. CONCLUSION M pneumoniae EM has a distinctive presentation compared with non-M pneumoniae EM, with more diffuse and atypical targets, more mucositis and respiratory tract sequelae. Histologic data show a TEN-like pattern in all M pneumoniae EM skin samples.
Collapse
Affiliation(s)
- Reyhan Amode
- Dermatology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France; Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Université Paris-Est Créteil (UPEC) Val de Marne, Créteil, France; Referral Center for Toxic Bullous Diseases, AP-HP, Henri Mondor Hospital, Créteil, France.
| | - Nicolas Ortonne
- Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France; UPEC, Créteil, France
| | - Touda Bounfour
- Dermatology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France
| | - Sabine Pereyre
- Université Bordeaux, National Institute for Agricultural Research, Mycoplasmal and Chlamydial Infections in Humans, Bordeaux, France; Bacteriology Department, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Frédéric Schlemmer
- Pneumology Department, AP-HP, Henri Mondor Hospital, Créteil and Département Hospitalo-Universitaire A-TVB (Ageing-Thorax-Vessel-Blood), UPEC, Créteil, France
| | - Emilie Bequignon
- Ear-Nose-Throat - Head and Neck Surgery Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Gérard Royer
- Ophthalmology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Pierre Wolkenstein
- Dermatology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France; Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Université Paris-Est Créteil (UPEC) Val de Marne, Créteil, France; Referral Center for Toxic Bullous Diseases, AP-HP, Henri Mondor Hospital, Créteil, France; UPEC, Créteil, France
| | - Olivier Chosidow
- Dermatology Department, Assistance Publique Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France; Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Université Paris-Est Créteil (UPEC) Val de Marne, Créteil, France; Referral Center for Toxic Bullous Diseases, AP-HP, Henri Mondor Hospital, Créteil, France; UPEC, Créteil, France
| |
Collapse
|
141
|
Visseaux L, Durlach A, Barete S, Beylot-Barry M, Bonnet N, Chassine A, Franck N, Herve G, Leclec'h C, Machet L, Ingen-Housz-Oro S, Petrella T, Vergier B, Ortonne N, Grange F. T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity. J Eur Acad Dermatol Venereol 2018; 32:1469-1475. [DOI: 10.1111/jdv.14805] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 01/03/2018] [Indexed: 10/18/2022]
Affiliation(s)
- L. Visseaux
- Service de Dermatologie; Hôpital Robert Debré; Reims France
| | - A. Durlach
- Laboratoire Pol Bouin; Hôpital Maison Blanche; Reims France
| | - S. Barete
- Service de Dermatologie; Hôpital Pitié-Salpêtrière; Paris France
| | - M. Beylot-Barry
- Service de Dermatologie; Hôpital Saint-André; Bordeaux France
| | - N. Bonnet
- Dermatologie; Institut Paoli Calmettes; Marseille France
| | | | - N. Franck
- Service de Dermatologie; Hôpital Cochin; Paris France
| | - G. Herve
- Service de Pathologie; Hôpital Pitié-Salpêtrière; Paris France
| | - C. Leclec'h
- Service de Dermatologie; CHU d'Angers; Angers France
| | - L. Machet
- Service de Dermatologie; Hôpital Trousseau; Tours France
| | | | - T. Petrella
- Department of Hematology-Oncology; University of Montréal; Montréal Canada
| | - B. Vergier
- Service de Pathologie; Hôpital Haut-Levêque; Pessac France
| | - N. Ortonne
- Service de Pathologie; Hôpital Henri Mondor; Créteil France
| | - F. Grange
- Service de Dermatologie; Hôpital Robert Debré; Reims France
| |
Collapse
|
142
|
Velter C, Hotz C, Ingen-Housz-Oro S, Wolkenstein P, Fardet L. Stevens-Johnson Syndrome During Pregnancy: Case Report of a Newborn Treated With the Culprit Drug. JAMA Dermatol 2018; 154:224-225. [PMID: 29261833 DOI: 10.1001/jamadermatol.2017.4607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Charles Velter
- AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France.,Referral Center for Toxic Bullous Diseases, Île-de-France, France
| | - Claire Hotz
- AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France.,Referral Center for Toxic Bullous Diseases, Île-de-France, France
| | - S Ingen-Housz-Oro
- AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France.,Referral Center for Toxic Bullous Diseases, Île-de-France, France.,EA EpiDermE 7379, UPEC Université Paris Est-Créteil Val-de-Marne, France
| | - Pierre Wolkenstein
- AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France.,Referral Center for Toxic Bullous Diseases, Île-de-France, France.,EA EpiDermE 7379, UPEC Université Paris Est-Créteil Val-de-Marne, France
| | - Laurence Fardet
- AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France.,Referral Center for Toxic Bullous Diseases, Île-de-France, France.,EA EpiDermE 7379, UPEC Université Paris Est-Créteil Val-de-Marne, France
| |
Collapse
|
143
|
Klejtman T, Beylot-Barry M, Joly P, Richard M, Debarbieux S, Misery L, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol 2017; 32:437-440. [DOI: 10.1111/jdv.14646] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 10/11/2017] [Indexed: 11/30/2022]
Affiliation(s)
- T. Klejtman
- Departement of Dermatology; AP-HP Hôpital Henri Mondor; Créteil France
| | - M. Beylot-Barry
- Departement of Dermatology; Hôpital Saint-André; CHU de Bordeaux; Bordeaux France
| | - P. Joly
- Departement of Dermatology; Hôpital Charles Nicolle; CHU de Rouen; Rouen France
| | - M.A. Richard
- Departement of Dermatology; Hopital de la Timone; Marseille France
- UMR 911; INSERM CRO2; Center for Research in Biological Oncology and Oncopharmacology; Timone Hospital Public Hospitals of Marseille; Aix-Marseille Univ; Marseille France
| | - S. Debarbieux
- Departement of Dermatology; Centre hospitalier Lyon-Sud; Lyon France
| | - L. Misery
- Departement of Dermatology; Centre hospitalier de Brest; Brest France
| | - P. Wolkenstein
- Departement of Dermatology; AP-HP Hôpital Henri Mondor; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
- Université Paris-Est Créteil Val de Marne (UPEC); Créteil France
| | - O. Chosidow
- Departement of Dermatology; AP-HP Hôpital Henri Mondor; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
- Université Paris-Est Créteil Val de Marne (UPEC); Créteil France
| | - S. Ingen-Housz-Oro
- Departement of Dermatology; AP-HP Hôpital Henri Mondor; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
| |
Collapse
|
144
|
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Department of dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- EA 7379-EpiDermE, Créteil, France
- Referral centre for severe cutaneous adverse reactions, Créteil, France
| | - Nicolas Ortonne
- University Paris-Est Val de Marne Créteil, UPEC, France
- Department of pathology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Olivier Chosidow
- Department of dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- EA 7379-EpiDermE, Créteil, France
- University Paris-Est Val de Marne Créteil, UPEC, France
- Referral centre for severe cutaneous adverse reactions, Créteil, France
| |
Collapse
|
145
|
Viarnaud A, Ingen-Housz-Oro S, Marque M, Valeyrie-Allanore L, Ortonne N, Gueudry J, Grootenboer-Mignot S, Muraine M, Bequignon E, Gagnière C, Schlemmer F, Wolkenstein P, Chosidow O. Severe sequelae of erythema multiforme: three cases. J Eur Acad Dermatol Venereol 2017; 32:e34-e36. [DOI: 10.1111/jdv.14478] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- A. Viarnaud
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
| | - S. Ingen-Housz-Oro
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
| | - M. Marque
- Dermatology; Caremeau hospital; Nîmes France
| | - L. Valeyrie-Allanore
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- Referral center for toxic bullous diseases; Créteil France
| | - N. Ortonne
- Department of Pathology; AP-HP, Henri Mondor hospital; Créteil France
| | - J. Gueudry
- Referral center for toxic bullous diseases; Créteil France
- Ophtalmology; Charles Nicolle hospital; Rouen France
| | | | - M. Muraine
- Referral center for toxic bullous diseases; Créteil France
- Ophtalmology; Charles Nicolle hospital; Rouen France
| | - E. Bequignon
- Otorhinolaryngology and Facial Cervical Surgery; Intercommunal Hospital; Intercommunal hospital; Créteil France
| | - C. Gagnière
- Gastro-enterology; AP-HP, Henri-Mondor hospital; Créteil France
| | - F. Schlemmer
- Pneumology; AP-HP, Henri Mondor hospital; Créteil France
| | - P. Wolkenstein
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
| | - O. Chosidow
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
- INSERM CIC 1430; Créteil France
| |
Collapse
|
146
|
Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, Caux F, Chapelon-Abric C, Debarbieux S, Delaporte E, Duval-Modeste AB, Fain O, Joly P, Marchand-Adam S, Monfort JB, Noël N, Passeron T, Ruivard M, Sarrot-Reynauld F, Verrot D, Bouvry D, Fardet L, Chosidow O, Sève P, Valeyre D. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol 2017; 153:681-685. [PMID: 28564695 DOI: 10.1001/jamadermatol.2017.1162] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Evidence for the long-term efficacy and safety of anti-tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis is lacking. Objective To determine the efficacy and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study. Design, Setting, and Participants STAT (Sarcoidosis Treated with Anti-TNF) is a French retrospective and prospective multicenter observational database that receives data from teaching hospitals and referral centers, as well as several pneumology, dermatology, and internal medicine departments. Included patients had histologically proven sarcoidosis and received anti-TNF between January 2004 and January 2016. We extracted data for patients with skin involvement at anti-TNF initiation. Main Outcomes and Measures Response to treatment was evaluated for skin and visceral involvement using the ePOST (extra-pulmonary Physician Organ Severity Tool) severity score (from 0 [not affected] to 6 [very severe involvement]). Epidemiological and cutaneous features at baseline, efficacy, steroid-sparing, safety, and relapses were recorded. The overall cutaneous response rate (OCRR) was defined as complete (final cutaneous ePOST score of 0 or 1) or partial response (ePOST drop ≥2 points from baseline but >1 at last follow-up). Results Among 140 patients in the STAT database, 46 had skin involvement. The most frequent lesions were lupus pernio (n = 21 [46%]) and nodules (n = 20 [43%]). The median cutaneous severity score was 5 and/or 6 at baseline. Twenty-one patients were treated for skin involvement and 25 patients for visceral involvement. Reasons for initiating anti-TNF were failure or adverse effects of previous therapy in 42 patients (93%). Most patients received infliximab (n = 40 [87%]), with systemic steroids in 28 cases (61%) and immunosuppressants in 32 cases (69.5%). The median (range) follow-up was 45 (3-103) months. Of the 46 patients with sarcoidosis and skin involvement who were treated with anti-TNF were included, median (range) age was 50 (14-78) years, and 33 patients (72%) were women. The OCRR was 24% after 3 months, 46% after 6 months, and 79% after 12 months. Steroid sparing was significant. Treatment was discontinued because of adverse events in 11 patients (24%), and 21 infectious events occurred in 14 patients (30%). Infections were more frequent in patients treated for visceral involvement than in those treated for skin involvement (n = 12 of 25 [48%] vs n = 2 of 21 [9.5%], respectively; P = .02). The relapse rate was 44% 18 months after discontinuation of treatment. Relapses during treatment occurred in 35% of cases, mostly during anti-TNF or concomitant treatment tapering. Conclusions and Relevance Anti-TNF agents are effective but suspensive in cutaneous sarcoidosis. The risk of infectious events must be considered.
Collapse
Affiliation(s)
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP Hôpital Henri Mondor, Créteil, France2Department of Dermatology, EA 7379 - EpiDermE, Université Paris Est, Créteil, France
| | - Alicia Marquet
- Department of Internal Medicine, Hôpital de la Croix-Rousse, Lyon, France
| | - Matthieu Mahevas
- Department of Internal Medicine, APHP Hôpital Henri Mondor, Créteil, France
| | - Didier Bessis
- Department of Dermatology, Hôpital Saint-Eloi, Montpellier, France
| | - Laurence Bouillet
- Department of Internal Medicine, Centre hospitalier universitaire de Grenoble-Alpes, Grenoble, France
| | - Frédéric Caux
- Department of Dermatology, APHP Hôpital Avicenne, Bobigny, France
| | | | | | | | | | - Olivier Fain
- Department of Internal Medicine, APHP Hôpital Saint-Antoine, Paris, France
| | - Pascal Joly
- Department of Dermatology, Hôpital Charles Nicolle, Rouen, France
| | | | | | - Nicolas Noël
- Department of Internal Medicine, APHP Hôpital Bicêtre Le Kremlin-Bicêtre, France
| | | | - Marc Ruivard
- Department of Internal Medicine, Hôpital Estaing, Clermont-Ferrand, France
| | - Françoise Sarrot-Reynauld
- Department of Internal Medicine, Centre hospitalier universitaire de Grenoble-Alpes, Grenoble, France
| | - Denis Verrot
- Department of Internal Medicine, Hôpital Saint-Joseph, Marseille, France
| | - Diane Bouvry
- Department of Pneumology, APHP Hôpital Avicenne, Bobigny, France
| | - Laurence Fardet
- Department of Dermatology, AP-HP Hôpital Henri Mondor, Créteil, France2Department of Dermatology, EA 7379 - EpiDermE, Université Paris Est, Créteil, France20Department of Dermatology, Université Paris Est UPEC, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, AP-HP Hôpital Henri Mondor, Créteil, France2Department of Dermatology, EA 7379 - EpiDermE, Université Paris Est, Créteil, France20Department of Dermatology, Université Paris Est UPEC, Créteil, France
| | - Pascal Sève
- Department of Internal Medicine, Hôpital de la Croix-Rousse, Lyon, France
| | | |
Collapse
|
147
|
Jannic A, Servy A, Chevalier X, Colin A, Chosidow O, Ingen-Housz-Oro S, Wolkenstein P. Self-diagnosed drug allergies: the belief of patients. J Eur Acad Dermatol Venereol 2017; 31:e524-e526. [DOI: 10.1111/jdv.14392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A. Jannic
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
| | - A. Servy
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
| | - X. Chevalier
- Rheumatology Department; AP-HP; Henri Mondor Hospital; Créteil France
- UPEC Université Paris-Est Créteil; Créteil France
| | - A. Colin
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
| | - O. Chosidow
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
- UPEC Université Paris-Est Créteil; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
| | - S. Ingen-Housz-Oro
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
| | - P. Wolkenstein
- Dermatology Department; AP-HP; Henri Mondor Hospital; Créteil France
- UPEC Université Paris-Est Créteil; Créteil France
- EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques); UPEC; Créteil France
| |
Collapse
|
148
|
Gardette E, Maraval A, Brunet-Possenti F, Quereux G, Beltraminelli H, Templier I, Hodel J, Scherman E, Durot E, Bagot M, Pham-Ledard A, Grange F, Beylot-Barry M, Ingen-Housz-Oro S. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J Eur Acad Dermatol Venereol 2017; 31:e498-e501. [PMID: 28543967 DOI: 10.1111/jdv.14358] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- E Gardette
- Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - A Maraval
- Neuroradiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - F Brunet-Possenti
- Dermatology, AP-HP, Bichat Hospital, Paris, France.,French Study Group of Cutaneous Lymphoma, GFELC, Paris, France
| | - G Quereux
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Nantes, Nantes, France
| | - H Beltraminelli
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, Inselspital, Bern University Hospital, Bern, France
| | - I Templier
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Grenoble, Grenoble, France
| | - J Hodel
- Neuroradiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Scherman
- Lymphoid Malignancies Unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Durot
- Hematology, University Hospital of Reims, Reims, France
| | - M Bagot
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, AP-HP, Saint-Louis Hospital, Paris, France
| | - A Pham-Ledard
- Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - F Grange
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Reims, Reims, France
| | - M Beylot-Barry
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - S Ingen-Housz-Oro
- Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,French Study Group of Cutaneous Lymphoma, GFELC, Paris, France
| |
Collapse
|
149
|
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389:2031-2040. [PMID: 28342637 DOI: 10.1016/s0140-6736(17)30070-3] [Citation(s) in RCA: 347] [Impact Index Per Article: 49.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/07/2016] [Accepted: 11/16/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with corticosteroid treatment alone, while decreasing treatment side-effects of corticosteroids. METHODS We did a prospective, multicentre, parallel-group, open-label, randomised trial in 25 dermatology hospital departments in France (Ritux 3). Eligible participants were patients with newly diagnosed pemphigus aged 18-80 years being treated for the first time (not at the time of a relapse). We randomly assigned participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24, then an additional visit at month 36). Treatment was assigned through central computer-generated randomisation, with stratification according to disease-severity (severe or moderate, based on Harman's criteria). The primary endpoint was the proportion of patients who achieved complete remission off-therapy at month 24 (intention-to-treat analysis). This study is registered with ClinicalTrials.gov, number NCT00784589. FINDINGS Between May 10, 2010, and Dec 7, 2012, we enrolled 91 patients and randomly assigned 90 to treatment (90 were analysed; 1 patient withdrew consent before the random assignment). At month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (absolute difference 55 percentage points, 95% CI 38·4-71·7; p<0·0001. This difference corresponded to a relative risk of success of 2·61 (95% CI 1·71-3·99, p<0·0001), corresponding to 1·82 patients (95% CI 1·39-2·60) who would need to be treated with rituximab plus prednisone (rather than prednisone alone) for one additional success. No patient died during the study. More severe adverse events of grade 3-4 were reported in the prednisone-alone group (53 events in 29 patients; mean 1·20 [SD 1·25]) than in the rituximab plus prednisone group (27 events in 16 patients; mean 0·59 [1·15]; p=0·0021). The most common of these events in both groups were diabetes and endocrine disorder (11 [21%] with prednisone alone vs six [22%] with rituximab plus prednisone), myopathy (ten [19%] vs three [11%]), and bone disorders (five [9%] vs five [19%]). INTERPRETATION Data from our trial suggest that first-line use of rituximab plus short-term prednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events. FUNDING French Ministry of Health, French Society of Dermatology, Roche.
Collapse
Affiliation(s)
- Pascal Joly
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France.
| | - Maud Maho-Vaillant
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | | | - Vivien Hebert
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Estelle Houivet
- Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France
| | - Sébastien Calbo
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Frédérique Caillot
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Marie Laure Golinski
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint Etienne, Saint Etienne, France
| | | | - Carle Paul
- Department of Dermatology, University of Toulouse, Toulouse, France
| | - Marie-Aleth Richard
- Department of Dermatology, Assistance Publique des Hopitaux de Marseille, Aix Marseille University, UMR 911, INSERM CRO2, Marseille, France
| | - Jean David Bouaziz
- Department of Dermatology of St Louis Hospital, Paris 7 Sorbonne Paris Cité University, Paris, France
| | - Sophie Duvert-Lehembre
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| | | | - Frederic Caux
- Department of Dermatology, University of Paris XIII, Bobigny, France
| | - Marina Alexandre
- Department of Dermatology, University of Paris XIII, Bobigny, France
| | | | - Pierre Vabres
- Department of Dermatology Dijon University Hospital, Dijon, France
| | | | - Gaelle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sebastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud; Pierre Bénite, Lyon, France
| | | | - Michel D'Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, University of Paris V, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Thomas Vermeulin
- Department of Medical Information and Informatics, Rouen University Hospital, Rouen, France
| | - Jacques Benichou
- Department of Biostatistics, Rouen University Hospital and INSERM U1219, Normandie University, Rouen, France
| | - Philippe Musette
- Department of Dermatology, Rouen University Hospital and INSERM U1234, Centre de référence des maladies bulleuses autoimmunes, Normandie University, Rouen, France
| |
Collapse
|
150
|
Gottlieb J, Ingen-Housz-Oro S, Alexandre M, Grootenboer-Mignot S, Aucouturier F, Sbidian E, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Hüe S, Bernardeschi C, Ortonne N, Caux F, Wolkenstein P, Chosidow O, Prost-Squarcioni C. Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. Br J Dermatol 2017; 177:212-222. [PMID: 27995619 DOI: 10.1111/bjd.15244] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Linear IgA bullous dermatosis (LABD) is a clinically and immunologically heterogeneous, subepidermal, autoimmune bullous disease (AIBD), for which the long-term evolution is poorly described. OBJECTIVES To investigate the clinical and immunological characteristics, follow-up and prognostic factors of adult idiopathic LABD. METHODS This retrospective study, conducted in our AIBD referral centre, included adults, diagnosed between 1995 and 2012, with idiopathic LABD, defined as pure or predominant IgA deposits by direct immunofluorescence. Clinical, histological and immunological findings were collected from charts. Standard histology was systematically reviewed, and indirect immunofluorescence (IIF) on salt-split skin (SSS) and immunoblots (IBs) on amniotic membrane extracts using anti-IgA secondary antibodies were performed, when biopsies and sera obtained at diagnosis were available. Prognostic factors for complete remission (CR) were identified using univariate and multivariate analyses. RESULTS Of the 72 patients included (median age 54 years), 60% had mucous membrane (MM) involvement. IgA IIF on SSS was positive for 21 of 35 patients tested; 15 had epidermal and dermal labellings. Immunoelectron microscopy performed on the biopsies of 31 patients labelled lamina lucida (LL) (26%), lamina densa (23%), anchoring-fibril zone (AFz) (19%) and LL+AFz (23%). Of the 34 IgA IBs, 22 were positive, mostly for LAD-1/LABD97 (44%) and full-length BP180 (33%). The median follow-up was 39 months. Overall, 24 patients (36%) achieved sustained CR, 19 (29%) relapsed and 35% had chronic disease. CR was significantly associated with age > 70 years or no MM involvement. No prognostic immunological factor was identified. CONCLUSIONS Patients with LABD who are < 70 years old and have MM involvement are at risk for chronic evolution.
Collapse
Affiliation(s)
- J Gottlieb
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France
| | - S Ingen-Housz-Oro
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - M Alexandre
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France
| | - S Grootenboer-Mignot
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Department of Autoimmunity and Hypersensitivity, APHP, Bichat Hospital, Paris, France
| | - F Aucouturier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Immunology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Sbidian
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - E Tancrede
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - P Schneider
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Regnier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tarnier Hospital, Paris, France
| | - C Picard-Dahan
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Bichat Hospital, Paris, France
| | - E Begon
- Dermatology Department, René-Dubos Hospital, Pontoise, France
| | - C Pauwels
- Dermatology Department, Saint-Germain Hospital, Saint-Germain, France
| | - K Cury
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tenon Hospital, Paris, France
| | - S Hüe
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Immunology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - C Bernardeschi
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - N Ortonne
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Pathology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - F Caux
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - P Wolkenstein
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - O Chosidow
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - C Prost-Squarcioni
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France.,Pathology Department, APHP, Avicenne Hospital, Bobigny, France
| |
Collapse
|